MAPKAPK2 and cancer: These results suggest that while ERK preferentially activates RSK, atypical activation is temporarily driven to rapidly trigger their cellular stress responses via the p38-MK2 pathway, for example, to escape from the cytotoxicity of anti-cancer agents.